Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

A Case Report of Successful Treatment of Crohn's Disease and Psoriasis With Guselkumab.

Grossberg LB.

Inflamm Bowel Dis. 2019 Mar 13. pii: izz033. doi: 10.1093/ibd/izz033. [Epub ahead of print] No abstract available.

PMID:
30863855
2.

Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.

Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, Merola JF, Ryan C, Siegel MP, Weinberg JM, Wu JJ, Van Voorhees AS.

J Am Acad Dermatol. 2018 Feb;78(2):383-394. doi: 10.1016/j.jaad.2017.06.043. Review.

PMID:
29332708
3.

Guselkumab for the Treatment of Psoriasis.

Machado Á, Torres T.

BioDrugs. 2018 Apr;32(2):119-128. doi: 10.1007/s40259-018-0265-6. Review.

PMID:
29470778
4.
5.

Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.

Gordon KB, Armstrong AW, Han C, Foley P, Song M, Wasfi Y, You Y, Shen YK, Reich K.

J Eur Acad Dermatol Venereol. 2018 Nov;32(11):1940-1949. doi: 10.1111/jdv.15012. Epub 2018 Jul 18.

PMID:
29706008
6.

Guselkumab for the treatment of moderate-to-severe plaque psoriasis.

Yang EJ, Sanchez IM, Beck K, Sekhon S, Wu JJ, Bhutani T.

Expert Rev Clin Pharmacol. 2018 Apr;11(4):333-344. doi: 10.1080/17512433.2018.1445967. Epub 2018 Mar 6. Review.

PMID:
29478344
8.

Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials.

Nakamura M, Lee K, Jeon C, Sekhon S, Afifi L, Yan D, Lee K, Bhutani T.

Dermatol Ther (Heidelb). 2017 Sep;7(3):281-292. doi: 10.1007/s13555-017-0187-0. Epub 2017 Jun 21. Review.

9.
10.

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.

Gordon KB, Duffin KC, Bissonnette R, Prinz JC, Wasfi Y, Li S, Shen YK, Szapary P, Randazzo B, Reich K.

N Engl J Med. 2015 Jul 9;373(2):136-44. doi: 10.1056/NEJMoa1501646.

11.

Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.

Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell K, Marciniak SJ Jr, Wasfi Y, Wang Y, Szapary P, Krueger JG.

J Allergy Clin Immunol. 2014 Apr;133(4):1032-40. doi: 10.1016/j.jaci.2014.01.025.

12.

Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.

Foley P, Gordon K, Griffiths CEM, Wasfi Y, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.

JAMA Dermatol. 2018 Jun 1;154(6):676-683. doi: 10.1001/jamadermatol.2018.0793.

13.

Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.

Papp KA, Blauvelt A, Kimball AB, Han C, Randazzo B, Wasfi Y, Shen YK, Li S, Griffiths CEM.

J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1515-1522. doi: 10.1111/jdv.14910. Epub 2018 Apr 10.

14.

First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.

Zhuang Y, Calderon C, Marciniak SJ Jr, Bouman-Thio E, Szapary P, Yang TY, Schantz A, Davis HM, Zhou H, Xu Z.

Eur J Clin Pharmacol. 2016 Nov;72(11):1303-1310. Epub 2016 Aug 11.

PMID:
27515978
15.

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.

Griffiths CEM, Papp KA, Kimball AB, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.

J Drugs Dermatol. 2018 Aug 1;17(8):826-832.

PMID:
30124721
16.

Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.

Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, Shen YK, You Y, Griffiths CEM.

Br J Dermatol. 2018 Jan;178(1):132-139. doi: 10.1111/bjd.16008. Epub 2017 Dec 14.

PMID:
28940259
17.

Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials.

Howell ST, Cardwell LA, Feldman SR.

Ann Pharmacother. 2018 Apr;52(4):380-387. doi: 10.1177/1060028017743268. Epub 2017 Nov 14.

PMID:
29134822
18.

Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.

Al-Salama ZT, Scott LJ.

Am J Clin Dermatol. 2018 Dec;19(6):907-918. doi: 10.1007/s40257-018-0406-1.

PMID:
30467781
19.
20.

Increased occurrence of psoriasis in patients with Crohn's disease and their relatives.

Lee FI, Bellary SV, Francis C.

Am J Gastroenterol. 1990 Aug;85(8):962-3.

PMID:
2375323

Supplemental Content

Support Center